Recruitment

Recruitment Status
Completed

Inclusion Criteria

staging of a known recurrence
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient who have signed an informed consent
...
staging of a known recurrence
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient who have signed an informed consent
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Search of the primary tumor, especially in the case of the inaugural discovery of metastases
Patient affiliated or beneficiary of regime of social security of a Member State of the European community
Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)

Exclusion Criteria

Pregnant or lactating woman
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
Patient unable to give their free and informed consent
...
Pregnant or lactating woman
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
Patient unable to give their free and informed consent
Patient with another evolutive cancer disease and/or treated for less than 5 years
Persons placed under judicial protection

Summary

Conditions
Neuroendocrine Tumors
Type
Observational
Design
  • Observational Model: Case-Only
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

staging of a known recurrence
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient who have signed an informed consent
...
staging of a known recurrence
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient who have signed an informed consent
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Search of the primary tumor, especially in the case of the inaugural discovery of metastases
Patient affiliated or beneficiary of regime of social security of a Member State of the European community
Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)

Exclusion Criteria

Pregnant or lactating woman
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
Patient unable to give their free and informed consent
...
Pregnant or lactating woman
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
Patient unable to give their free and informed consent
Patient with another evolutive cancer disease and/or treated for less than 5 years
Persons placed under judicial protection

Tracking Information

NCT #
NCT02134639
Collaborators
Not Provided
Investigators
  • Principal Investigator: Philippe FERNANDEZ, Professor University Hospital, Bordeaux
  • Philippe FERNANDEZ, Professor University Hospital, Bordeaux
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2023